Navigation Links
Schizophrenic in Medical News
Improving the prognosis for schizophrenic disorders
Throughout the world, scientists are attempting to recognize and treat schizophrenic disorders at an earlier stage. It is hoped that this will improve the prognosis, which has often been unfavorable. In the latest edition of Deutsches rzteblatt International ( Dtsch Arztebl Int 2008; 105[30]: 5...Cognitive rehabilitation holds promise for schizophrenic brain function improvements
Study had shown that it is possible to improve the brain functions of schizophrenic// patients through cognitive rehabilitation programs. Researchers from Washington University in St. Louis have suggested that memorization strategies used by normal people to remember things may be useful for s...Music to help schizophrenic patients
Scientists have found that in addition to schizophrenic patients being given medical care, music, as a therapy, can bring about changes in their general sense of well being, mental state and social activities.// Since 1950s music had been used as a therapy for people with serious mental disord......comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...
Columbia leads national effort to develop early intervention for schizophrenia
...ders by dramatically slowing progression; reducing disability, mortality, and the expense of care; and increasing recovery. The Recovery After Initial schizophrenic Episode (RAISE) study, funded at $9.9 million for two years, has the potential to be extended to six years and a total of $21.3 million if certain mil...Study finds cancer is the second most frequent cause of death in individuals with schizophrenia
...tify characteristics that might help predict which schizophrenic patients are likely to develop cancer. The rese...he general population (56.3 vs. 33.0%). In female schizophrenic patients, the risk of death due to breast cancer w...ing less attention to symptoms; the difficulty for schizophrenic patients to benefit from optimum treatment; and le......t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...
Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference
...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications
...including SEROQUEL. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen......t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...
Schizophrenic in Medical Technology
Conference Call Scheduled for Today - Tuesday, September 2, 2008 at 5:00 p.m. Eastern Time
MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from
its first Phase 3 clinical trial of ...
...of patients experience continued symptoms despite treatment. The problem with current therapies is that none of them improve the cognitive deficit in schizophrenic patients, and almost all of these drugs have significant side effects, such as weight gain, induction of tremors and psychological depression. ...
...ndidates in clinical development. Alexza's lead program is AZ-004 (Staccato loxapine) that is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is pro...
... the positive data from our first Phase 3 trial in schizophrenic patients -- reinforce our belief that AZ-004 is a ...olunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and pharmacokinetic study in non-agitated schizophrenic patients, a 344 patient Phase 3 study in schizophr...
...mpairments play a primary role in the inability of schizophrenic patients to function normally. It has been estimated that there are 7.9 million schizophrenic patients in the world's seven major pharmaceutical markets and that the majority of all schizophrenic patients are cognitively impaired. About...
... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorper...
... Phase 2 study, and a 32 patient multiple-dose tolerability and PK study in schizophrenic patients. The Company believes that the unique delivery of loxapine via t...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ......of patients experience continued symptoms despite treatment. The problem with current therapies is that none of them improve the cognitive deficit in schizophrenic patients, and almost all of these drugs have significant side effects, such as weight gain, induction of tremors and psychological depression. ...
...ndidates in clinical development. Alexza's lead program is AZ-004 (Staccato loxapine) that is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is pro...
... the positive data from our first Phase 3 trial in schizophrenic patients -- reinforce our belief that AZ-004 is a ...olunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and pharmacokinetic study in non-agitated schizophrenic patients, a 344 patient Phase 3 study in schizophr...
...mpairments play a primary role in the inability of schizophrenic patients to function normally. It has been estimated that there are 7.9 million schizophrenic patients in the world's seven major pharmaceutical markets and that the majority of all schizophrenic patients are cognitively impaired. About...
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
... developed for the treatment of acute agitation in schizophrenic or bipolar disorder patients," said Thomas B. King...ollment in its first Phase 3 clinical trial of 344 schizophrenic patients with acute agitation at 24 U.S. clinical ... loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testin...Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
...olunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and PK study in non-agitated schizophrenic patients, and a 344 patient Phase 3 study in agitated schizophrenic patients. Alexza projects that the initial results...... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorper...
... Phase 2 study, and a 32 patient multiple-dose tolerability and PK study in schizophrenic patients. The Company believes that the unique delivery of loxapine via t...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...
Schizophrenic in Biological News
Advances in the field of schizophrenia research: New genetic factors identified
...ding to estimates, approximately one in every hundred persons experiences a schizophrenic episode at least once in their lives. In Germany alone there are approximat...proximately 80 percent according to estimations. Thus, close relatives of a schizophrenic patient are more susceptible to fall ill themselves. The hereditary pattern...Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs
...ticular gene, such as BRAC1, can be tested and then treated with protocols designed specifically for them, we want to be able to know enough about the schizophrenic brain to target treatments to individual patients. The next step for the researchers is to find the many genes whose expression is controlled by t...New treatment mechanisms for schizophrenia
...chizophrenia. These findings suggest that 7 nAChR agonists including SSR180711 could be potential therapeutic drugs for cognitive deficits in schizophrenic patients. In the third investigation, Semenova and colleagues show that a recently discovered brain receptor for serotonin (5-HT7) might be of impo...The influence of the menstrual cycle on the female brain
...can result in disorders such as addictions and is also implicated in various psychiatric and neurological pathologies, such as Parkinson's disease and schizophrenic disorders. Many studies on animals prove that the dopaminergic3 system is sensitive to gonadal steroid hormones (estrogen, progesterone). For example,...Engineered mouse mimics cognitive aspects of schizophrenia
...cs. The achievement is important, because creating an animal model of any schizophrenic characteristics has not been done before. And schizophrenia's genetic and p...neurons. Also, amphetamines, which release dopamine, are known to aggravate schizophrenic symptoms. The researchers also based their experiments on evidence that ...Schizophrenic in Biological Technology
...t comfort and convenience.
Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...
...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...
...ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is pro...
... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato pr...
... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorper...
...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...
Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference
...ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ......ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is pro...
Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB
...ro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegrating tablet t...FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
...ncluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment...Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation
... has five product candidates in active clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed enrollment of its first Phase 3 clinical trial. A second Phase 3 clinical trial ...... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato pr...
... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorper...
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
...its first Phase 3 clinical trial, designed to enroll approximately 300 schizophrenic patients with acute agitation at 25 U.S. clinical centers. The trial ...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...Other TagsOther Contents
SenoScanSenographeStellateProcyonOjemannIntegraDepthalonCortacMiditronUrisysElectrodeUltrAblatorKompressorEasyView
(Date:5/23/2013)... characterized as "triple negative" carries a poor prognosis, with ... kill the cancer cells the way it,s supposed to. ... cells don,t respond to chemotherapy, and identifies a mechanism ... Dr. Shawn Li, PhD, and his team at Western,s ... protein called Numb functions to promote the death of ...
(Date:5/23/2013)... Former United States Vice President Dick Cheney served ... Paramedic Luncheon. , In front of 1,500 guests ... medics, saying, "I am delighted to be here to ... of the Year Award. I think it's a tremendous ... within a company like this because there are obviously ...
(Date:5/23/2013)... May 23, 2013 On April 29th, 2013, ... midst of growing numbers of H7N9 cases and deaths. The ... Bird Flu Cases Will Subside in Northern Hemisphere as Available ... new cases have been reported. , Quoting Kevin McGuire, ... as predictable as flowers budding in the spring and leaves ...
(Date:5/23/2013)... EnvirOasis, the leader in energy efficient ... is pleased to announce its new line of Energy ... EnvirOasis has been a market leader in Fluorescent ... and has recently brought to market a full line ... is energy efficient lighting technology which produces a very ...
(Date:5/23/2013)... Doheny HealthDay Reporter , , THURSDAY, May 23 (HealthDay ... dropping sharply, especially among Hispanic teens, according to a new ... aged 15 to 19 dropped by nearly one half from ... 1,000 teens to 31 births for every 1,000. From ... fell 25 percent, from 41.5 to about 31. During ...
Breaking Medicine News(10 mins):Health News:Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3[0] Research identifies a way to make cancer cells more responsive to chemotherapy[0] Acadian Ambulance Honors Paramedic of the Year at Annual Luncheon[0] UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine[0] EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products[0] U.S. Teen Birth Rate Plummets: Report
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
(Date:5/22/2013)... physicists have developed a novel technique that can detect ... process that is one of the most important, though ... in a paper in Nature , post-doctoral researcher ... Melanie Schnell of the Center for Free-Electron Laser Science ... on finely-tuned microwave fields to identify molecular variants apart, ...
(Date:5/22/2013)... acids in fish oil have long been thought to ... Heart Association currently recommends eating at least two servings ... omega 3s. However, the mechanism behind this protective effect ... led by Jason R. Carter of Michigan Technological University ... fish oil might specifically counteract the detrimental effects of ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |